Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
95% CI, 0.75-0.98
Another triple agonist (HM15211) is undergoing phase 1 clinical trials with no published data so far
Higher NAD+ levels upregulate these pathways
Collectively, these results validate TMT-TAILs as an effective strategy for off-target substrate nomination and suggest that X(PC) induces a multipathway cell death response by cleaving endogenous caspase targets across both apoptotic and inflammatory pathways
US$ 24.92
US$ 29.57
US$ 26.13
US$ 23.23
US$ 24.42
US$ 25.77
US$ 22.70
US$ 26.48
